Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
Amgen looks for Five Prime payback
A key pivotal study of bemarituzumab will read out shortly.
What future for Lag3 blockade?
Opdualag chalks up another failure, this time in the extension of an approved use.
The month ahead: February’s upcoming events
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
A Leap into the subgroups
On a wing and a prayer Leap heads for phase 3.
